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 Pediatric multiple sclerosis (MS) is a rare disease, 
which has been increasingly recognized in the last years. 
It is defined by onset before the age of 18 years and was 
previously known as early onset MS and juvenile MS.
 Pediatric MS is considered a multifactorial disease, in 
which the chronic inflammatory demyelination of the central 
nervous system (CNS) is caused by a combination of genetic 
vulnerability and environmental triggers. These triggers are 
still being investigated with controversial results, such as 
viral infections, inadequate exposure to sunlight, vitamin D 
deficiency and exposure to cigarette smoke.
 The global incidence of pediatric MS is unknown and 
few epidemiological studies exhibit diverse results from 
0.5 to 0.9 per 100,000. It is estimated that 3% - 10% of all 
patients with MS will have onset before 18 and less than 
1% before 10 years of age.1 The female preponderance 
is also seen in adolescent-onset MS, however prevalence 
is similar for female and male in early childhood-onset.1 
A positive family history is present in 6% - 8% of children 
with MS, moreover, parents and other relatives of pediatric-
onset MS patients are themselves at risk for typical MS 
onset.
 The Portuguese multicentre study in pediatric MS that is 
now published involved 46 patients,2 recruited in 4 hospitals. 
In 6 cases the onset of disease occurred before 12 years of 
age and one patient has a positive family history of disease. 
The mean age at the first manifestation was 14 years and at 
confirmation of MS diagnosis was 16.1 years old. 
 Banwell et al published a systematic review of 1,540 
pediatric MS patients, 50% - 70% of them with a polyfocal 
presentation.1 The most frequent clinical manifestations 
were motor dysfunction (30%), sensory dysfunction (15% 
- 30%), brainstem symptoms (25%), optic neuritis (10% - 
22%) and ataxia (5% - 15%); isolated transverse myelitis 
occurred in less than 10%.1 The first attack of the younger 
patients (less than 10 years) was more likely to display 
polyfocal deficits and altered behavior or consciousness, 
fulfilling criteria for acute disseminated encephalomyelitis 
(ADEM). Over 96% of these 1,540 pediatric patients had 
an initial relapsing-remitting course and relapses frequently 
occurred in the first 1 - 2 years.1
 According to International consensus clinical criteria, 
diagnosis of pediatric MS can be established in patients 
younger than 18 years with two episodes of CNS 
demyelination separated by more than 30 days and 
involving more than one area of the CNS, fulfilling clinical 
and radiological criteria of dissemination in time and space.3 
The most recent revision of the McDonald criteria accepts 
MRI evidence of dissemination in a first typical clinical event; 
however in children less than 12 years of age these criteria 
are of less predictive value and should not be applied in 
ADEM like presentations.3
 The MRI features of pediatric MS are quite similar to adult 
MS and involve the presence of multiple lesions, mostly in 
the white matter and typically observed in the periventricular 
area of the corpus callosum and spinal cord.4 Children 
often show more infratentorial lesions, predominantly in 
the pons, and may present large and tumefactive lesions 
with perilesional edema.4 A recommended minimum 
diagnostic panel for the initial inflammatory demyelinating 
event should define the disease burden with brain and 
cervical spinal cord MRI with and without gadolinium.5 
The International Pediatric Multiple Sclerosis Study Group 
strongly recommended additional imaging of the entire 
spinal cord to identify demyelinating disorders with different 
treatment approaches.5
 The diagnostic work-up should also include a 
cerebrospinal fluid (CSF) analysis, which is important to 
provide information regarding the inflammatory process, 
contributing to support the diagnosis and rule out other 
disorders that may display similar clinical or radiological 
findings. CSF cell count and protein are normal in almost 
60% of pediatric MS patients, but the others present mild 
pleocytosis or increase in protein concentration. This 
diagnosis is supported by finding an increase in IgG index or 
oligoclonal IgG bands in over 90% of cases, although these 
can be absent in the presentation and only detected later 
in the disease course. The presence of oligoclonal bands 
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in a first clinical CNS demyelinating event is correlated with 
evolution to MS.
 At the initial presentation, it may be very difficult to 
distinguish pediatric MS from ADEM, which in a small sub-
set of children may be associated with later development 
of MS, thus strengthening the importance of a prolonged 
follow-up.
 As in adults, the differential diagnosis of pediatric 
MS, includes infeccious, inflammatory, vascular and 
neoplastic disorders, but additionally metabolic/genetic 
neurodegenerative disorders must be considered in this 
age group, namely mitochondriopathies, leukodystrophies 
and organic and aminoacidopathies.5
 Pediatric MS can be considered a big challenge, 
since the younger children may display atypical clinical 
presentation (fever, encephalopathy, involvement of 
peripheral nervous system or other organ systems), 
absence or minimal resolution of symptoms, a progressive 
disease course, neuroradiological and laboratory features 
(elevated erythrocyte sedimentation rate, leukocytosis, 
marked CSF pleocytosis and absence of isolated CSF 
oligoclonal IgG).5 The presence of any of these features 
should lead to consideration of disorders other than MS.5
 Such as in adult population, the first line treatment 
used for an acute demyelinating event is intravenous 
methylprednisolone pulse.6 If there is an incomplete 
response or in severe attacks, intravenous immunoglobulin 
and plasmapheresis should be considered.6 Since there 
are no randomized controlled studies in pediatric MS, 
the disease modifying therapies that intend to prevent 
relapses, are extrapolated from adult clinical trials and 
small retrospective, observational studies.6 The first 
line therapies are interferons or glatiramer acetate, with 
growing data supporting their efficacy and safety. In case 
of refractory disease, the use of natalizumab, daclizumab, 
cyclophosphamide and fingolomod are associated with 
increased risk of important side effects.6
 A multidisciplinary team including pediatric and adult 
neurologists, psychologist, nurse, social worker, physio-
therapist and occupational therapist, is crucial to promote a 
high quality care for these young patients.
 While adult neurologists are more experienced in 
following large cohorts of MS patients and regularly up- 
dated with the most recent clinical trials concerning 
preventive therapy, the pediatric neurologists feel more 
familiar with the differential diagnosis with infectious, 
metabolic and genetic neurodegenerative disorders in this 
age group and with the repercussions in school performance 
and behavior. 
 The cognitive dysfunction and psychological distress 
related to the direct neurologic impairment and the impact 
of the diagnosis of a chronic illness in adolescence should 
be recognized and may require an intervention in the 
functioning at home, school and among peers.
 In my opinion “Pediatric Multiple Sclerosis in Portugal: 
A Multicentre Study”2 should be considered as an important 
first step towards a larger multicentre study, including 
more hospitals all around the country, where children and 
adolescents with MS are regularly followed. 
 The demographic, clinical, laboratorial and neuro-
radiological characteristics of the Portuguese patients are 
similar to those reported in previous studies. Concerning the 
comparison between the characteristics of childhood-onset 
MS (< 12 years) and adolescent-onset MS (12 - 18 years) 
it was found a male preponderance and CSF pleocytosis 
among the younger group. As expected, the analysis of the 
preventive treatments prescribed to pediatric MS patients 
in Portugal revealed a preference for interferons and 
glatiramer acetate.
 The increase of awareness about pediatric MS and a 
closer collaboration between pediatric and adult neurologist 
centers would be a great opportunity to promote long-term 
studies in demyelinating disorders and to share knowledge, 
in order to improve the care of these children/adolescents 
and their families.
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